Presentations & Publications

Presentation

Phase 1/2 study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial

SITC, November 5, 2015

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases & breaking Advaxis news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.